120 filings
8-K
OTLK
Outlook Therapeutics Inc
15 Apr 24
Unregistered Sales of Equity Securities
4:53pm
8-K
OTLK
Outlook Therapeutics Inc
12 Apr 24
Other Events
4:04pm
8-K
OTLK
Outlook Therapeutics Inc
2 Apr 24
Other Events
4:15pm
8-K
OTLK
Outlook Therapeutics Inc
26 Mar 24
Departure of Directors or Certain Officers
4:20pm
8-K
OTLK
Outlook Therapeutics Inc
18 Mar 24
Unregistered Sales of Equity Securities
5:14pm
8-K
cpzt3a10 c54j2
7 Mar 24
Amendments to Articles of Incorporation or Bylaws
4:16pm
8-K
widur92
14 Feb 24
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
4:40pm
8-K
nj84f6ickd
24 Jan 24
Entry into a Material Definitive Agreement
6:02am
8-K
j0jspj1v4 cu
22 Dec 23
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
4:15pm
8-K
9ua5j
6 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
210blw0httqtdco
2 Nov 23
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
8:12am
8-K
8py47k3sp
20 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
vjeyw3vde7pu
30 Aug 23
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
6:21am
8-K
bqu de33vbg
14 Aug 23
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
4:15pm
8-K
mdkcaumi98320z43 939
16 May 23
Entry into a Material Definitive Agreement
6:01am
8-K
f2uno6hrnc5xo5fjk
15 May 23
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
4:33pm
8-K/A
gl2z81ix u1936w
3 Apr 23
Amendments to Articles of Incorporation or Bylaws
4:37pm
8-K
6nvsrvdmn
30 Mar 23
Amendments to Articles of Incorporation or Bylaws
4:02pm
8-K
q1cnb6psi
14 Feb 23
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
8:14am
8-K
53is30giucm
29 Dec 22
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
9:16am